FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045509256> ?p ?o ?g. }

• W2045509256 endingPage "318" @default.
• W2045509256 startingPage "307" @default.
• W2045509256 abstract "To evaluate the safety, immunogenicity, and biologic effects of chimeric monoclonal anti-CD4 (cM-T412) in patients with refractory rheumatoid arthritis (RA), and to obtain preliminary data on the clinical response to this treatment.Twenty-five patients with active refractory RA were treated with incremental doses (10 to 700 mg) of cM-T412 in an open-label, escalating-dose phase I trial.Infusion with cM-T412 was followed by an immediate, rapid decline in CD4+ T cells. The level of circulating CD4+ T cells remained depressed in most patients even at 6 months posttreatment. Following antibody infusion, proliferative responses of peripheral blood lymphocytes to mitogens and antigens were determined; mitogen and antigen responses were decreased compared with pretreatment responses. Mitogen responses tended to return to baseline values more rapidly than did responses to antigen. Adverse events included fever (19 patients), which was associated with myalgias, malaise, and asymptomatic hypotension; these symptoms were self-limited and appeared to correlate with transient elevations in interleukin-6. No significant human antibody response to the cM-T412 variable region was detected; only 2 patients developed transiently low levels of antibodies reactive with cM-T412. Significant clinical improvement, defined as > or = 50% decrease in tender joint counts compared with baseline, was noted in 43% of patients at 5 weeks and 33% at 6 months following cM-T412 infusion.Treatment of refractory RA with cM-T412 appears to be safe and is associated with sustained decreases in circulating CD4+ T cell counts and depressed in vitro T cell responses. No significant human antichimeric antibody response was detected. Nonblinded assessment of clinical end points suggests that treatment with cM-T412 may have beneficial effects in these patients with refractory RA. A double-blind clinical trial is warranted to determine its clinical efficacy in treating RA." @default.
• W2045509256 created "2016-06-24" @default.
• W2045509256 creator A5001211705 @default.
• W2045509256 creator A5003503432 @default.
• W2045509256 creator A5025358988 @default.
• W2045509256 creator A5033838025 @default.
• W2045509256 creator A5038941107 @default.
• W2045509256 creator A5042266507 @default.
• W2045509256 creator A5047996868 @default.
• W2045509256 creator A5066780563 @default.
• W2045509256 creator A5076421665 @default.
• W2045509256 creator A5078983281 @default.
• W2045509256 creator A5089748359 @default.
• W2045509256 creator A5091475719 @default.
• W2045509256 date "1993-03-01" @default.
• W2045509256 modified "2023-10-05" @default.
• W2045509256 title "Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis" @default.
• W2045509256 cites W1703039404 @default.
• W2045509256 cites W1975243493 @default.
• W2045509256 cites W1984001403 @default.
• W2045509256 cites W1986778299 @default.
• W2045509256 cites W1987930131 @default.
• W2045509256 cites W1993662593 @default.
• W2045509256 cites W2003913420 @default.
• W2045509256 cites W2015865604 @default.
• W2045509256 cites W2027912654 @default.
• W2045509256 cites W2036403810 @default.
• W2045509256 cites W2040505385 @default.
• W2045509256 cites W2042818781 @default.
• W2045509256 cites W2050641852 @default.
• W2045509256 cites W2065019144 @default.
• W2045509256 cites W2073302853 @default.
• W2045509256 cites W2088158803 @default.
• W2045509256 cites W2091943129 @default.
• W2045509256 cites W2093599503 @default.
• W2045509256 cites W2095029406 @default.
• W2045509256 cites W2095188728 @default.
• W2045509256 cites W2102421659 @default.
• W2045509256 cites W2108891346 @default.
• W2045509256 cites W2116594823 @default.
• W2045509256 cites W2131840622 @default.
• W2045509256 cites W2133692536 @default.
• W2045509256 cites W2135067735 @default.
• W2045509256 cites W2143053368 @default.
• W2045509256 cites W2151246967 @default.
• W2045509256 cites W2152348310 @default.
• W2045509256 cites W2337516302 @default.
• W2045509256 doi "https://doi.org/10.1002/art.1780360304" @default.
• W2045509256 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8095785" @default.
• W2045509256 hasPublicationYear "1993" @default.
• W2045509256 type Work @default.
• W2045509256 sameAs 2045509256 @default.
• W2045509256 citedByCount "116" @default.
• W2045509256 countsByYear W20455092562012 @default.
• W2045509256 countsByYear W20455092562014 @default.
• W2045509256 countsByYear W20455092562015 @default.
• W2045509256 countsByYear W20455092562018 @default.
• W2045509256 crossrefType "journal-article" @default.
• W2045509256 hasAuthorship W2045509256A5001211705 @default.
• W2045509256 hasAuthorship W2045509256A5003503432 @default.
• W2045509256 hasAuthorship W2045509256A5025358988 @default.
• W2045509256 hasAuthorship W2045509256A5033838025 @default.
• W2045509256 hasAuthorship W2045509256A5038941107 @default.
• W2045509256 hasAuthorship W2045509256A5042266507 @default.
• W2045509256 hasAuthorship W2045509256A5047996868 @default.
• W2045509256 hasAuthorship W2045509256A5066780563 @default.
• W2045509256 hasAuthorship W2045509256A5076421665 @default.
• W2045509256 hasAuthorship W2045509256A5078983281 @default.
• W2045509256 hasAuthorship W2045509256A5089748359 @default.
• W2045509256 hasAuthorship W2045509256A5091475719 @default.
• W2045509256 hasBestOaLocation W20455092561 @default.
• W2045509256 hasConcept C126322002 @default.
• W2045509256 hasConcept C142424586 @default.
• W2045509256 hasConcept C147483822 @default.
• W2045509256 hasConcept C159654299 @default.
• W2045509256 hasConcept C163864487 @default.
• W2045509256 hasConcept C197934379 @default.
• W2045509256 hasConcept C203014093 @default.
• W2045509256 hasConcept C2777077863 @default.
• W2045509256 hasConcept C2777575956 @default.
• W2045509256 hasConcept C2777910003 @default.
• W2045509256 hasConcept C2780868878 @default.
• W2045509256 hasConcept C542903549 @default.
• W2045509256 hasConcept C71924100 @default.
• W2045509256 hasConcept C86803240 @default.
• W2045509256 hasConcept C87355193 @default.
• W2045509256 hasConcept C90924648 @default.
• W2045509256 hasConceptScore W2045509256C126322002 @default.
• W2045509256 hasConceptScore W2045509256C142424586 @default.
• W2045509256 hasConceptScore W2045509256C147483822 @default.
• W2045509256 hasConceptScore W2045509256C159654299 @default.
• W2045509256 hasConceptScore W2045509256C163864487 @default.
• W2045509256 hasConceptScore W2045509256C197934379 @default.
• W2045509256 hasConceptScore W2045509256C203014093 @default.
• W2045509256 hasConceptScore W2045509256C2777077863 @default.
• W2045509256 hasConceptScore W2045509256C2777575956 @default.
• W2045509256 hasConceptScore W2045509256C2777910003 @default.
• W2045509256 hasConceptScore W2045509256C2780868878 @default.

• next